Catalyst

Slingshot members are tracking this event:

Final results from Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B expected in the fourth quarter of 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CTRV Community voting in process

Additional Information

Additional Relevant Details
The Phase 2a trial will enroll 60 treatment-naïve patients with chronic HBV infection. This study will consist of a sequential dose escalation, with 10 patients per cohort receiving four weeks of a once-daily dose of either 5, 10, 25, 50 or 100 mg of CMX157, plus two patients per cohort receiving 300 mg of TDF, the standard dose of Viread. As in the Phase 1b study, initiation of each higher dose cohort will follow review of the data from the previous cohort, and there will be another DSMB review between the 25 mg and 50 mg CMX157 cohorts. Final results from this study are expected in the fourth quarter of 2016.
http://ir.contravir....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cmx157, Tenofovir Df, Viread, Antiviral, Hepatitis B